EASL Selects Albireo’s A4250 Data for Late Breaker Presentation
05 April 2017 - 10:00PM
Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, today announced that clinical data from the ongoing
Phase 2 study of its lead product candidate A4250 in children with
cholestatic liver disease has been selected by the European
Association for the Study of the Liver (EASL) for an oral
presentation during the late breaker session at The International
Liver Congress™ (ILC) 2017 being held April 19-23, 2017, at the RAI
Amsterdam in Amsterdam.
Details of the presentation are as follows:
Title: The Ileal Bile Acid Transport inhibitor
A4250 decreases pruritus and serum bile acids in cholestatic liver
diseases – an ongoing multiple dose, open-label, multicentre
studySession: Late BreakerDate /
Time: Saturday, April 22, 4:45 p.m. – 5:00 p.m.
CETLocation: Hall 5Presenter: Dr.
Ulrich Baumann, Professor of Pediatric Gastroenterology and
Hepatology at Hannover Medical School, Germany
EASL’s ILC, now in its 52nd year, is a multi-disciplinary
scientific Congress which brings more than 10,000 clinicians and
scientists together annually to discuss clinical innovation and
research. For more information about the conference, visit
https://ilc-congress.eu/.
About Albireo Albireo is a clinical-stage
biopharmaceutical company focused through its operating subsidiary
on the development of novel bile acid modulators to treat orphan
pediatric liver diseases and other liver and gastrointestinal
diseases and disorders. Albireo’s clinical pipeline includes two
Phase 2 product candidates and one Phase 3 product candidate.
Albireo was spun out from AstraZeneca in 2008.
Albireo Pharma is located in Boston, Massachusetts, and its key
operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.
For more information on Albireo, please visit
http://www.albireopharma.com.
Source: Albireo Pharma, Inc.
Investor Contact:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2024 to May 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From May 2023 to May 2024